836 Shares in argenx SE (NASDAQ:ARGX) Purchased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. bought a new stake in argenx SE (NASDAQ:ARGX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 836 shares of the company's stock, valued at approximately $453,000.

A number of other institutional investors also recently modified their holdings of the business. J.Safra Asset Management Corp lifted its position in argenx by 590.0% during the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company's stock worth $30,000 after purchasing an additional 59 shares during the period. Blue Trust Inc. lifted its holdings in shares of argenx by 620.0% in the second quarter. Blue Trust Inc. now owns 72 shares of the company's stock worth $28,000 after acquiring an additional 62 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company's stock worth $51,000 after acquiring an additional 40 shares during the last quarter. Cromwell Holdings LLC lifted its holdings in shares of argenx by 73.3% in the third quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock worth $85,000 after acquiring an additional 66 shares during the last quarter. Finally, Point72 Hong Kong Ltd bought a new position in shares of argenx in the second quarter worth about $76,000. Institutional investors own 60.32% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ARGX shares. Citigroup increased their target price on shares of argenx from $512.00 to $635.00 and gave the stock a "buy" rating in a report on Thursday, October 17th. Wolfe Research raised argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 price objective for the company in a research note on Tuesday, November 12th. William Blair raised argenx from a "market perform" rating to an "outperform" rating in a research note on Friday, November 1st. Evercore ISI upped their price objective on argenx from $675.00 to $706.00 and gave the company an "outperform" rating in a research note on Thursday. Finally, Wedbush upped their price objective on argenx from $519.00 to $560.00 and gave the company an "outperform" rating in a research note on Friday, July 26th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $630.42.

argenx Price Performance

Shares of argenx stock traded up $6.86 during trading hours on Friday, hitting $603.60. 203,022 shares of the company's stock traded hands, compared to its average volume of 309,605. argenx SE has a 12-month low of $327.73 and a 12-month high of $611.22. The stock has a market capitalization of $36.09 billion, a price-to-earnings ratio of -682.21 and a beta of 0.61. The company has a fifty day simple moving average of $555.08 and a 200-day simple moving average of $485.94.

argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. During the same period last year, the firm posted ($1.25) EPS. On average, analysts forecast that argenx SE will post 2.2 EPS for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.